ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Other SEDAR Filings

 

Other SEDAR Filings 2020
  • Download PDF Documents
    CEO FORM 52-109FV2 - Q1 2020
    Acting CFO FORM 52-109FV2 Certification of Interim Filings - Q1 2020
    CEO FORM 52-109FV2-Q2 2020
    Acting CFO FORM 52-109FV2 Certification of Interim Filings
    CEO FORM 52-109FV2-Q3 2020
    Acting CFO FORM 52-109FV2-Q3 2020
    CEO FORM 52-109FV2 - Q4 2020
    Acting CFO FORM 52-109FV2 Certification of Interim Filings - Q4 2020
Other SEDAR Filings 2019
  • Download PDF Documents
    CEO FORM 52-109FV2 Certification of Interim Filings
    Acting CFO FORM 52-109FV2 Certification of Interim Filings
    CEO FORM 52-109FV2 Certification of Interim Filings
    Acting CFO FORM 52-109FV2 Certification of Interim Filings
    CEO FORM 52-109FV2 Certification of Interim Filings
    Acting CFO FORM 52-109FV2 Certification of Interim Filings
    CEO FORM 52-109FV2 Certification of Interim Filings
    Acting CFO FORM 52-109FV2 Certification of Interim Filings
Other SEDAR Filings 2018
  • Download PDF Documents
    Acting CFO Certification of Annual Filings 52-109fv1 CFO 2018-01-29
    CEO Certification of Annual Filings 52-109fv1 CEO 2018-01-29
    Acting CFO FORM 52-109FV2 - Q3 - 2018-08-29
    CEO FORM 52-109FV2 - Q3 - 2018-08-29
Other SEDAR Filings 2017
  • Download PDF Documents
    NI Card 2017-03-07
    Acting CFO Certification of Annual Filings 52-109fv1 CFO 2017-01-30
    CEO Certification of Annual Filings 52-109fv1 CEO 2017-01-30
    Acting CFO Certification of Annual Filings 52-109fv1 CFO 2017-03-01
    CEO Certification of Annual Filings 52-109fv1 CEO 2017-03-01
    Other 2017-03-07
Other SEDAR Filings 2016
  • Download PDF Documents
    Certification of Annual Filings 52-109fv1 CEO 2016-01-28
    Certification of Annual Filings 52-109fv1 CFO 2016-01-28
    Q3 Certification of Annual Filings 52-109fv1 Acting CFO 2016-08-30
    Q3 Certification of Annual Filings 52-109fv1 CEO 2016-08-30
Other SEDAR Filings 2015
  • Download PDF Documents
    Certification of Interim Filings 52-109fv2 CEO 2015-01-28
    Certification of Interim Filings 52-109fv2 CFO 2015-01-28
    Certification of Interim Filings 52-109fv2 CEO 2015-03-02
    Certification of Interim Filings 52-109fv2 CFO 2015-03-02
    Certification of Interim Filings 52-109fv2 CEO 2015-06-01
    Certification of Interim Filings 52-109fv2 CFO 2015-06-01
    Certification of Interim Filings 52-109fv2 CEO 2015-08-31
    Certification of Interim Filings 52-109fv2 CFO 2015-08-31
Other SEDAR Filings 2014
  • Download PDF Documents
    Certification of Interim Filings 52-109fv2 CEO 2014-01-28
    Certification of Interim Filings 52-109fv2 CFO 2014-01-28
    Certification of Interim Filings 52-109fv2 CEO 2014-03-03
    Certification of Interim Filings 52-109fv2 CFO 2014-03-03
    Certificate Re Dissemination to Shareholders 2014-03-05
    Form of Proxy 2014-03-05
    Other 2014-03-05
    Other 2014-03-07
    Certification of Interim Filings 52-109fv2 CEO 2014-05-30
    Certification of Interim Filings 52-109fv2 CFO 2014-05-30
Other SEDAR Filings 2013
  • Download PDF Documents
    Certification of Interim Filings 52-109fv2 CEO 2013-01-29
    Certification of Interim Filings 52-109fv2 CFO 2013-01-29
    Certification of Interim Filings 52-109fv2 CEO 2013-03-01
    Certification of Interim Filings 52-109fv2 CFO 2013-03-01
    Certification Re Dissemination to Shareholders 2013-03-08
    Other 2013-03-08
    Certification of Interim Filings 52-109fv2 CEO 2013-05-30
    Certification of Interim Filings 52-109fv2 CFO 2013-05-30
    Certification of Interim Filings 52-109fv2 CEO 2013-08-29
    Certification of Interim Filings 52-109fv2 CFO 2013-08-29
    Form of Proxy 2013-03-08
Other SEDAR Filings 2012
  • Download PDF Documents
    Certification of Interim Filings 52-109fv2 CEO 2012-01-30
    Certification of Interim Filings 52-109fv2 CFO 2012-01-30
    Certification of Interim Filings 52-109fv2 CEO 2012-02-29
    Certification of Interim Filings 52-109fv2 CFO 2012-02-29
    Certificate Re Dissemination to Shareholders 2012-03-08
    Form of Proxy 2012-03-08
    Other 2012-03-08
    Certification of Interim Filings 52-109fv2 CEO 2012-05-30
    Certification of Interim Filings 52-109fv2 CFO 2012-05-30
    Certification of Interim Filings 52-109fv2 CEO 2012-08-29
    Certification of Interim Filings 52-109fv2 CFO 2012-08-29
    Certification of Refiled Interim Filings 52-109f2r CEO 2012-10-01
    Certification of Refiled Interim Filings 52-109f2r CFO 2012-10-01

Recent News

March 4th 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Read More
February 26th 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Other SEDAR Filings
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us